scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1083535021 |
P356 | DOI | 10.1245/S10434-017-5789-3 |
P698 | PubMed publication ID | 28160137 |
P50 | author | Ian D McGilvray | Q50073694 |
Aloysious Aravinthan | Q53134884 | ||
Hla-Hla Thein | Q56997867 | ||
Markus Selzner | Q87749637 | ||
P2093 | author name string | Eberhard L Renner | |
Mamatha Bhat | |||
Anand Ghanekar | |||
David R Grant | |||
Mark S Cattral | |||
Paul D Greig | |||
Gonzalo Sapisochin | |||
Nazia Selzner | |||
Nicolas Goldaracena | |||
Leslie B Lilly | |||
Assaf Issachar | |||
Silvio G Bruni | |||
Adam C Doyle | |||
Boraiah Sreeharsha | |||
P2860 | cites work | Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival | Q46743120 |
Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. | Q47700671 | ||
Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. | Q51715162 | ||
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation | Q26772329 | ||
Management of hepatocellular carcinoma: An update | Q27860530 | ||
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
Liver transplantation for advanced hepatocellular carcinoma | Q28074653 | ||
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
Defining long-term outcomes with living donor liver transplantation in North America | Q30356729 | ||
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience | Q34630506 | ||
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing | Q36716640 | ||
The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). | Q37133637 | ||
Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria | Q37252475 | ||
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis | Q37341959 | ||
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. | Q37348887 | ||
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
The place of downstaging for hepatocellular carcinoma | Q37729494 | ||
Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach | Q38168622 | ||
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. | Q38706131 | ||
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients | Q38886929 | ||
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
Health care costs associated with hepatocellular carcinoma: a population-based study | Q39489363 | ||
Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics | Q39585608 | ||
Defining Benchmarks for Major Liver Surgery: A multicenter Analysis of 5202 Living Liver Donors | Q39585622 | ||
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study | Q39766876 | ||
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study | Q40741790 | ||
Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation | Q41208111 | ||
Role of liver transplantation in cancer therapy | Q41374922 | ||
Live donor liver transplantation in high MELD score recipients. | Q43254448 | ||
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging | Q43883499 | ||
The global NAFLD epidemic | Q44238213 | ||
Hepatocellular carcinoma: Ablate and wait versus rapid transplantation | Q45146349 | ||
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. | Q46682103 | ||
P433 | issue | 7 | |
P304 | page(s) | 1843-1851 | |
P577 | publication date | 2017-02-03 | |
P1433 | published in | Annals of Surgical Oncology | Q2853069 |
P1476 | title | Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma | |
P478 | volume | 24 |
Q92519577 | Extremes of Liver Transplantation for Hepatocellular Carcinoma |
Q88791892 | Hepatocellular carcinoma: when is liver transplantation oncologically futile? |
Q55275430 | Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. |
Q92796957 | Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience |
Search more.